ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Antiplatelet or anticoagulation after mitral valve repair?

Thursday, April 28, 2016

Submitted by

Stuart Head

Source

Source Name: J Thorac Cardiovasc Surg

Source URL: https://www.ncbi.nlm.nih.gov/pubmed/?term=26832208

Author(s)

Paparella D, Di Mauro M, Bitton Worms K, Bolotin G, Russo C, Trunfio S, Scrofani R, Antona C, Actis Dato G, Casabona R, Colli A, Gerosa G, Renzulli A, Serraino F, Scrascia G, Zaccaria S, De Bonis M, Taramasso M, Delgado L, Tritto F, Marmo J, Parolari A, Myaseodova V, Villa E, Troise G, Nicolini F, Gherli T, Whitlock R, Conte M, Barili F, Gelsomino S, Lorusso R, Sciatti E, Marinelli D, Di Giammarco G, Calafiore AM, Sheikh A, Alfonso JJ, Glauber M, Miceli A; GIROC Investigators.

In a large multi-center, propensity-matched study, Paparella et al found that antiplatelet therapy as opposed to oral anticoagulation therapy initiated after mitral valve repair as antithrombotic prophylaxis caused significantly less major bleeding, which also caused mortality to be less by a 5-fold than with anticoagulation therapy.